Category: Investment, Biotech, Pharma
Biopharma Stock News Alert: SUNSHINE BIOPHARMA (OTCQB: SBFM) EXPANSION AND FINANCING OPPORTUNITIES FOR Adva-27a CANCER DRUG CANDIDATE: Company to RE-DOMICILE IN CANADA
Ideas get bigger when you share them...
Visit this company: Sunshine Biopharma Inc.
Montreal, Quebec, Canada - December 4, 2013 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. ( OTCQB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is re-domiciling the Company in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations. To this end, The Company filed a Schedule 14-C Information Statement on September 16, 2013 and an S-4 Registration Statement on October 23, 2013.
"We are very pleased that the re-domiciling process is going smoothly", said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Re-domiciling the Company in Canada will give us access to a more favorable fiscal environment and provide with greater flexibility to execute our business plan. This will better position our Company for expansion and allow us to capitalize on growth opportunities as our Adva-27a drug candidate enters the clinic."
Adva-27a is Sunshine Biopharma’s lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.